Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1718118

registered interest
date	14/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the findings of the first quarterly report of the National Audit of Metastatic Breast Cancer, published on 10 April, what steps they are taking to address gaps in data collection for secondary breast cancer patients.
tabling member printed	Baroness Merron
uin	HL4630
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.</p> answering member printed Lord Markham question first answered 24/05/2024 13:50:50 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718119

registered interest
date	14/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to improve the collection and reporting of ethnicity data for breast cancer patients to support understanding of variations in outcomes and patient experience of NHS care.
tabling member printed	Baroness Merron
uin	HL4631
answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.</p><p>The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.</p><p>NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.</p><p>NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.</p> answering member printed Lord Markham grouped question UIN HL4629 question first answered 21/05/2024 11:11:25 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1695050

registered interest
date	11/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made on the Government's major conditions strategy with specific reference to breast cancer; and if she will make a statement.
tabling member constituency	Norwich North
tabling member printed	Chloe Smith
uin	17863
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>In the development of the Major Conditions Strategy, we are considering how we improve outcomes for people in this country living with multiple conditions. Aligning work across several groups of conditions including cancer for this strategy, will allow us to focus on where there are similarities in approach and ensure care is better centred around the patient, maximising existing resources both within patient pathways and in integrating between pathways.</p><p> </p><p>Improving early diagnosis of cancer, including breast cancer, is a priority for the Government. The National Health Service has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. We know that breast cancer remains the most common cancer in England, with over 49,000 people being diagnosed each year. Thanks to advances in screening, treatment, and care, alongside NHS awareness campaigns, more women are surviving the disease than ever before.</p><p> </p><p>The NHS Cancer Programme has also commissioned five new cancer clinical audits, including primary and metastatic breast cancers. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, will increase the consistency of access to treatments, and help stimulate improvements in cancer treatment and outcomes for patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/03/2024 15:03:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1609 label Biography information for Chloe Smith

1624403

registered interest
date	27/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to provide specific funding for increasing the number of staff in the breast cancer workforce who deliver systemic anti-cancer treatment.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	183164
answer	answer is ministerial correction date of answer 15/05/2023 answer text <p>In 2023/24 NHS England will fund an expansion of cancer and diagnostics specialists, including those who will deliver systemic anti-cancer treatment. This includes, additional medical training places including for clinical/medical oncology, radiology, histopathology, and gastroenterology, grants to enable over 1,000 cancer nurse specialists and chemotherapy nurses to step into these roles or support their development in-role and a wider workforce development through establishing diagnostic training academies, including breast imaging and developing cancer support worker training.</p><p>Spending plans for individual budgets for 2024/25, including for the cancer workforce, are subject to a detailed financial planning exercise and will be finalised in due course. Spending plans for subsequent years will be subject to future spending reviews.</p> answering member constituency Colchester answering member printed Will Quince question first answered 15/05/2023 12:16:39 answering member 4423 label Biography information for Will Quince previous answer version 72939 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1624177

registered interest
date	26/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the number of breast clinical and medical oncologists to meet patient demand.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	182922
answer	answer is ministerial correction date of answer 15/05/2023 answer text <p>No specific assessment has been made. The Government has committed to publishing the NHS Long Term Workforce Plan. This will include independently verified forecasts for the number of healthcare professionals required in future years, taking full account of improvements in retention and productivity. This Plan is due to be published shortly.</p> answering member constituency Colchester answering member printed Will Quince question first answered 15/05/2023 15:44:43 answering member 4423 label Biography information for Will Quince previous answer version 72522 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1624178

registered interest
date	26/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) reduce shortages in the NHS breast cancer workforce and (b) increase the capacity of breast cancer services.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	182923
answer	answer is ministerial correction date of answer 03/05/2023 answer text <p>Health Education England and NHS England provided £81 million of investment in 2022/23 to support increased capacity and capability in the cancer and diagnostics workforce, many of whom will support breast cancer pathways.</p><p>To increase capacity of breast cancer services, the Government provided £10 million of funding for 28 new breast screening units and nearly 60 life-saving upgrades to services in the areas where they are most needed, so more women can be checked for signs of cancer. NHS England is also funding a new clinical audit on breast cancer to provide evidence to increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients.</p><p> </p><p>In addition, the Government has committed to publishing the Long-Term Workforce Plan which will help ensure that we have the right numbers of staff, with the right skills to transform and deliver high quality services fit for the future. This Plan is due to be published shortly.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 03/05/2023 10:22:29 answering member 4527 label Biography information for Helen Whately previous answer version 72524 answering member constituency Faversham and Mid Kent answering member printed Helen Whately answering member 4527 label Biography information for Helen Whately
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1611068

registered interest
date	17/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer in England.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL7158
answer	answer is ministerial correction date of answer 02/05/2023 answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p> answering member printed Lord Markham grouped question UIN HL7159 question first answered 02/05/2023 16:08:20 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1611069

registered interest
date	17/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with the devolved administrations regarding the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL7159
answer	answer is ministerial correction date of answer 02/05/2023 answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p> answering member printed Lord Markham grouped question UIN HL7158 question first answered 02/05/2023 16:08:20 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1609681

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure awareness of metastatic breast cancer among NHS staff involved in primary care.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179814
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>In April 2020, NHS England introduced the 'early cancer diagnosis service specification' for Primary Care Networks (PCNs), which 99% of general practices (GPs) are signed up to. This is designed to support improvements in rates of early cancer diagnosis by requiring PCNs to review the quality of their practices’ referrals for suspected cancer and take steps to improve this.</p><p>NHS England is supporting GPs to diagnose more cancers early by making funding available to embed clinical decision support tools within general practice. These tools are designed to support GPs in clinical decision making, such as whether to refer or request further diagnostic investigation in patients where they believe there is a risk of cancer, and identifying patients who may be at risk of cancer based on the symptoms they present with.</p><p>Cancer education programmes such as ‘Gateway C’ are available online and include specific courses on breast cancer, and face-to-face education sessions have now resumed and are offered by a range of providers.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 25/04/2023 11:47:39 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609682

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that all patients with primary breast cancer have an end of treatment summary in order to speed up detection of secondary breast cancer.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179815
answer	answer is ministerial correction date of answer 20/04/2023 answer text <p>The NHS Long Term Plan states that, where appropriate, every person diagnosed with cancer will have access to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. This includes provision of end of treatment summaries, empowering people to manage their care and the impact of their cancer.</p><p>The introduction of tailored follow up pathways for people after their initial breast cancer treatment has ensured there are clear access points for people with worrying symptoms or concerns to speak immediately to someone in the cancer team. Breast cancer-tailored follow up, which includes ‘patient initiated follow up’ or ‘open access follow up’ for suitable patients, is now in place in 95% of trusts.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 20/04/2023 09:55:22 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch